MktsMarkets

Larimar Therapeutics, Inc.
NASDAQ: LRMRKey statistics
LRMR News
Stories mentioning LRMR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 25,031 | 59,373 | 44,931 | 23,368 | 26,552 | 26,738 | 13,919 | 19,682 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 31,117 | 64,018 | 49,499 | 27,792 | 31,188 | 31,293 | 18,264 | 24,599 |
| Operating Income (Loss) | (31,117) | (64,018) | (49,499) | (27,792) | (31,188) | (31,293) | (18,264) | (24,599) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Net Income (Loss) | (29,613) | (62,498) | (47,712) | (26,182) | (29,281) | (28,824) | (15,499) | (21,627) |
| Earnings Per Share (Basic) | (0.61) | (0.41) | (0.46) | (0.47) | (0.24) | (0.34) | ||
| Earnings Per Share (Diluted) | (0.61) | (0.41) | (0.46) | (0.47) | (0.24) | (0.34) | ||
| Weighted Average Shares Outstanding (Basic) | 78,325 | 64,028 | 63,964 | 61,256 | 63,806 | 63,802 | ||
| Weighted Average Shares Outstanding (Diluted) | 78,325 | 64,028 | 63,964 | 61,256 | 63,806 | 63,802 | ||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About LRMR
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a stock listed on the Nasdaq Stock Market under the ticker symbol LRMR. It last traded at $2.35 (Oct 23, 2026, 9:30 AM ET), up 3.5% on the day. That gives Larimar Therapeutics a market capitalisation of $252.4M.
Over the past 52 weeks LRMR has traded between $1.92 and $6.42.
For the quarter ended Mar 31, 2026 it reported a net loss of $29.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$29.6M |
| Dec 31, 2025 | — | -$62.5M |
| Sep 30, 2025 | — | -$47.7M |
| Jun 30, 2025 | — | -$26.2M |
From Larimar Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…